Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis.

CONCLUSION: ABA, used as first-line biological treatment or after 1 or more anti-TNF agents, induces a comparable improvement in severe refractory JIA-related uveitis. PMID: 27633826 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27633826?dopt=Abstract

Source: J Rheumatol - September 14, 2016 Category: Rheumatology Authors: Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, Deslandre CJ, Falcini F, Alessio M, La Torre F, Denisova E, Martini G, Nikishina I, Zulian F Tags: J Rheumatol Source Type: research